Kolorektal Kanserlerde Th17 İlişkili IL-17, IL-21 ve IL-22 Sitokinlerinin Ekspresyon Düzeylerinin Belirlenmesi
xmlui.mirage2.itemSummaryView.MetaDataShow full item record
Immune system cells and released cytokines in tumor microenvironment have a very important role in cancer prognosis. Also, T-helper 17 (Th17) cells have been frequently found in many tumors microenvironment and their effects on the clinical outcomes are not fully understood. The aim of this study was to evaluate serum levels of Th17 related cytokines IL-17A, IL-21, and IL-22 and their correlation with clinicopathologic parameters of colorectal cancer. 40 (19F) patients with colorectal cancer and 40 (18F) healthy controls included in the study. Preoperative blood samples were collected from the patients for measurement of IL-17A, IL-21 and IL-22 serum levels (pg/ml) using ELISA and the results were compared with the levels in healthy controls. Correlation between serum interleukin levels and stage, differentiation, lymph node invasion, perineural and lymphovascular invasions, the presence of metastasis were also evaluated. IL-17A, IL-21 and IL-22 levels as pg/ml were 3,11 (2,99-3,73), 108,3 (11,9-1394) ve 38,8 (38,4-42,9) respectively in patients with colonic cancer. Whereas, they were 1,3 (0,7-6,2), 123,12 (61,8-1157,6) ve 15,44 (0,15-143,9) pg/ml respectively in healthy controls. IL-17A and IL-22 were found to be increased significantly in patients with colorectal cancer (p<0.001).The cut-off value for the significance of IL-17A was found to be 2,755 pg/ml and cut-off value for IL-22 was found to be 35.63 pg/ml. Any values over these were found to be correlated with colonic cancer (p<0.001). We couldn't find any correlation between interleukin expression levels and tumor differentiation, Modified Astler-Coller, the presence of lymph nodes metastasis, lymphovascular invasion, perineural invasion, and di stant metastasis. In conclusion, systemic expression of IL-17A and IL-22 increases in patients with colorectal cancer. Therefore, patients with increased serum levels of IL-17A and IL-22 should be evaluated further for colorectal cancer.